{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:26:03Z","timestamp":1792099563136,"version":"4.4.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10384-025-01254-8","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T08:33:19Z","timestamp":1753173199000},"page":"117-122","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Six-month comparative outcomes of aflibercept and faricimab in treatment-na\u00efve macular edema secondary to branch retinal vein occlusion"],"prefix":"10.1007","volume":"70","author":[{"given":"Taiichi","family":"Hikichi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Kurabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amane","family":"Notoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuuna","family":"Oguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misaki","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeka","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"1254_CR1","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/S0140-6736(20)31559-2","volume":"396","author":"IU Scott","year":"2020","unstructured":"Scott IU, Campochiaro PA, Newman NJ, Biousse V. Retinal vascular occlusions. Lancet. 2020;396:1927\u201340.","journal-title":"Lancet"},{"key":"1254_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ophtha.2013.08.038","volume":"121","author":"PA Campochiaro","year":"2014","unstructured":"Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology. 2014;121:209\u201319.","journal-title":"Ophthalmology"},{"key":"1254_CR3","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.ophtha.2011.12.005","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012;119:802\u20139.","journal-title":"Ophthalmology"},{"key":"1254_CR4","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.ophtha.2016.02.030","volume":"123","author":"R Tadayoni","year":"2016","unstructured":"Tadayoni R, Waldstein SM, Boscia F, Gerding H, Pearce I, Priglinger S, et al. Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER. Ophthalmology. 2016;123:1332\u201344.","journal-title":"Ophthalmology"},{"key":"1254_CR5","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/j.ophtha.2017.06.027","volume":"124","author":"R Tadayoni","year":"2017","unstructured":"Tadayoni R, Waldstein SM, Boscia F, Gerding H, Gekkieva M, Barnes E, et al. Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study. Ophthalmology. 2017;124:1778\u201387.","journal-title":"Ophthalmology"},{"key":"1254_CR6","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ophtha.2015.09.035","volume":"123","author":"WL Clark","year":"2016","unstructured":"Clark WL, Boyer DS, Heier JS, Haller JA, Vitti R, Kazmi H, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology. 2016;123:330\u20136.","journal-title":"Ophthalmology"},{"key":"1254_CR7","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s40266-017-0458-6","volume":"34","author":"SM Hoy","year":"2017","unstructured":"Hoy SM. Aflibercept: a review in macular oedema secondary to branch retinal vein occlusion. Drugs Aging. 2017;34:393\u2013400.","journal-title":"Drugs Aging"},{"key":"1254_CR8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/09273948.2019.1681474","volume":"29","author":"B K\u00fc\u00e7\u00fck","year":"2021","unstructured":"K\u00fc\u00e7\u00fck B, Sirakaya E, Karaca C. Comparison of ranibizumab versus aflibercept in treating macular edema among patients with serous retinal detachment secondary to branch retinal vein occlusion. Ocul Immunol Inflamm. 2021;29:403\u201310.","journal-title":"Ocul Immunol Inflamm"},{"key":"1254_CR9","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1177\/1120672120904669","volume":"31","author":"HDJ Hogg","year":"2021","unstructured":"Hogg HDJ, Simplicio SD, Pearce MS. Ranibizumab and aflibercept intravitreal injection for treatment-na\u00efve and refractory macular oedema in branch retinal vein occlusion. Eur J Ophthalmol. 2021;31:548\u201355.","journal-title":"Eur J Ophthalmol"},{"key":"1254_CR10","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","volume":"126","author":"J Sahni","year":"2021","unstructured":"Sahni J, Patel SS, Dugel PU, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial. Ophthalmology. 2021;126:1155\u201370.","journal-title":"Ophthalmology"},{"key":"1254_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2023.100302","volume":"3","author":"LO Hattenbach","year":"2023","unstructured":"Hattenbach LO, Abreu F, Arrisi P, Basu K, Danzig C, Guymer R, et al. BALATON and COMINO: phase III randomized clinical trials of faricimab for retinal vein occlusion study design and rationale. Opthalmol Sci. 2023;3: 100302.","journal-title":"Opthalmol Sci."},{"key":"1254_CR12","doi-asserted-by":"publisher","first-page":"8583348","DOI":"10.1155\/2024\/8583348","volume":"2024","author":"SV Savant","year":"2024","unstructured":"Savant SV, Kwan JT, Barouch CJ, Ramsey DJ, Marx J, et al. Durability and efficacy of faricimab in treatment-resistant retinal edema utilizing \u201creal-world\u201d dosing regimens. J Ophthalmol. 2024;2024:8583348.","journal-title":"J Ophthalmol"},{"key":"1254_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2022-001188","volume":"7","author":"R Wang","year":"2022","unstructured":"Wang R, McClard CK, Laswell S, Mamoudzadeh R, Salabati M, Ammar M, et al. Quantifying burden of intravitreal injections: questionnaire assessment of life impact of treatment by intravitreal injections (QUALTII). BMJ Open Ophthalmol. 2022;7: e001188.","journal-title":"BMJ Open Ophthalmol"},{"key":"1254_CR14","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12886-019-1208-9","volume":"19","author":"V Daien","year":"2019","unstructured":"Daien V, Eldem BM, Talks JS, Korobelnik J-F, Mitchell P, Fnger RP, et al. Real-world data in retinal diseases treated with anti-vascular endothelial growth factor (anti-VEGF) therapy\u2014systemic approach to identify and characterized data sources. BMC Ophthalmol. 2019;19:206.","journal-title":"BMC Ophthalmol"},{"key":"1254_CR15","unstructured":"Chugai Pharmaceutical Co., Ltd. Faricimab approval for retinal vein occlusion in Japan.\u00a0Chugai News Release. Published 26 March 2024. https:\/\/www.chugai-pharm.co.jp\/english\/news\/detail\/20240326160000_1054.html Accessed 2 April 2025."},{"key":"1254_CR16","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1186\/s12886-022-02682-7","volume":"22","author":"W Zhang","year":"2022","unstructured":"Zhang W, Liu Y, Sang A. Efficacy and effectiveness of anti-VEGF or steroids monotherapy versus combination treatment for macular edema secondary to retinal vein occlusion: a systematic review and meta-analysis. BMC Ophthalmol. 2022;22:472.","journal-title":"BMC Ophthalmol"},{"key":"1254_CR17","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.3390\/jcm12082909","volume":"12","author":"H Sasajima","year":"2023","unstructured":"Sasajima H, Zako M, Murotani K, Ueta Y, Tachi N, Ishida H, et al. Visual prognostic factors in eyes with subretinal fluid associated with branch retinal vein occlusion. J Clin Med. 2023;12:2909.","journal-title":"J Clin Med"},{"key":"1254_CR18","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0002-9394(14)70001-7","volume":"117","author":"SS Hayreh","year":"1994","unstructured":"Hayreh SS, Zimmerman B, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol. 1994;117:429\u201341.","journal-title":"Am J Ophthalmol"},{"key":"1254_CR19","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1136\/bmj.310.6973.170","volume":"310","author":"JM Bland","year":"1995","unstructured":"Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. BMJ. 1995;310:170.","journal-title":"BMJ"},{"key":"1254_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaophthalmol.2013.5515","volume":"132","author":"SS Hayreh","year":"2014","unstructured":"Hayreh SS, Zimmerman MB. Branch retinal vein occlusion. Natural history of visual outcome. JAMA Ophthalmol. 2014;132:13\u201322.","journal-title":"JAMA Ophthalmol"},{"key":"1254_CR21","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.ophtha.2010.01.060","volume":"117","author":"RL McIntosh","year":"2010","unstructured":"McIntosh RL, Rogers SL, Lim L, Cheung N, Wang JJ, Mitchell P, et al. Natural history of central retinal vein occlusion: an evidence-based systemic review. Ophthalmology. 2010;117:1113-23.e15.","journal-title":"Ophthalmology"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01254-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-025-01254-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01254-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:35:59Z","timestamp":1772166959000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-025-01254-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1254"],"URL":"https:\/\/doi.org\/10.1007\/s10384-025-01254-8","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T. Hikichi, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Novartis, Bayer, Chugai); H. Kurabe, None; A. Notoya, None; Y. Oguro, None; M. Hirano, None; Y. Doi, None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}